scholarly journals Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 12477-12488 ◽  
Author(s):  
Hojjat Ahmadzadehfar ◽  
Elisabeth Eppard ◽  
Stefan Kürpig ◽  
Rolf Fimmers ◽  
Anna Yordanova ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Metastatic Prostate Cancer ◽  
Therapeutic Response ◽  
Radioligand Therapy ◽  
Castrate Resistant

Patient-Specific Dosimetry in Radioligand Therapy (RLT) for Metastatic Prostate Cancer Using 177Lu-DKFZ-PSMA-617

2021 ◽  
Author(s):  
Elahe Mahmoudi ◽  
Elahe Pirayesh ◽  
Mohammad Reza Deevband ◽  
Mahasti Amoui ◽  
Mehrdad Ghorbani Rad ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Patient Specific ◽  
Radioligand Therapy

Radioligand therapy with 177 Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

2016 ◽  
Vol 43 (12) ◽  
pp. 835 ◽  
Author(s):  
Hojjat Ahmadzadehfar ◽  
Markus Essler ◽  
Michael Schäfers ◽  
Kambiz Rahbar
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Clinical Use ◽  
Radioligand Therapy

scholarly journals Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Ayun Cassell ◽  
Bashir Yunusa ◽  
Mohamed Jalloh ◽  
Medina Ndoye ◽  
Mouhamadou M. Mbodji ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Cost Effective ◽  
Androgen Deprivation ◽  
Sub Saharan Africa ◽  
International Agency ◽  
Castrate Resistant Prostate Cancer ◽  
Sub Saharan ◽  
Castrate Resistant

The estimated incidence rate of prostate cancer in Africa was 22.0/100,000 in 2016. The International Agency for Research on Cancer (IARC) has cited prostate cancer as a growing health threat in Africa with approximated 28,006 deaths in 2010 and estimated 57,048 deaths in 2030. The exact incidence of advanced and metastatic prostate cancer is not known in sub-Saharan Africa. Hospital-based reports from the region have shown a rising trend with most patients presenting with advanced or metastatic disease. The management of advanced and metastatic prostate cancer is challenging. The available international guidelines may not be cost-effective for an African population. The most efficient approach in the region has been surgical castration by bilateral orchidectomy or pulpectomy. Medical androgen deprivation therapy is expensive and may not be available. Patients with metastatic castrate-resistant prostate cancer tend to be palliated due to the absence or cost of chemotherapy or second-line androgen deprivation therapy in most of Africa. A cost-effective guideline for developing nations to address the rising burden of advanced prostate cancer is warranted at this moment.

Bilateral Orchiectomy With or Without Flutamide for Metastatic Prostate Cancer

2021 ◽  
pp. 73-76
Author(s):  
Philipp Dahm
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Randomized Trial ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Bilateral Orchiectomy

This chapter summarizes the findings of a landmark randomized trial comparing total androgen deprivation in the form of bilateral orchiectomy plus the antiandrogen flutamide to bilateral orchiectomy alone. The study found no survival benefit but did find increased side effects from the addition of an antiandrogen.

Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617

2016 ◽  
Vol 41 (7) ◽  
pp. 572-573 ◽  
Author(s):  
Carl Diedrich Schlenkhoff ◽  
Eberhard Knüpfer ◽  
Markus Essler ◽  
Hojjat Ahmadzadehfar
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Hormone Response ◽  
Radioligand Therapy

Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4687-4687 ◽  
Author(s):  
D. R. Shepard ◽  
A. Weil ◽  
J. A. Garcia ◽  
R. Dreicer ◽  
D. Raghavan
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Elderly Men ◽  
Castrate Resistant

New radioligand therapy with 177Lu-PSMA-617 in men with metastatic prostate cancer: Initial clinical experience after 50 therapy cycles.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16575-e16575
Author(s):  
Martin Boegemann ◽  
Axel Bode ◽  
Matthias Weckesser ◽  
Nemanja Avramovic ◽  
Michael Claesener ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Experience ◽  
Metastatic Prostate Cancer ◽  
Radioligand Therapy ◽  
Initial Clinical Experience

Patterns of response to androgen deprivation therapy in younger patients with locally advanced or metastatic prostate cancer.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 324-324
Author(s):  
Matthew Keating ◽  
Lisa Giscombe ◽  
Andre Desouza ◽  
Shiva Kumar Reddy Mukkamalla ◽  
Ritesh Rathore
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Locally Advanced ◽  
Androgen Deprivation ◽  
Standards Of Care ◽  
National Cancer Database ◽  
Castrate Resistant Prostate Cancer ◽  
Castrate Resistant

324 Background: Androgen deprivation therapy (ADT) remains a standard of care in the treatment of locally advanced prostate cancer. But thanks to a few key trials (STAMPEDE, CHAARTED, and LATITUDE) reported within the past three years, docetaxel and abiraterone now have roles in extending overall survival in a patient population traditionally treated with ADT alone. These treatments when combined with ADT have been shown to extend overall survival in metastatic hormone-sensitive prostate cancer patients. The role of ADT in relation to other therapies continues to evolve rapidly. We intend to revisit ADT’s longstanding role in prostate cancer treatment using a national cancer database. Our aim is to look beyond traditional standards of care to identify patients more likely to have overall survival benefit from ADT. Are there any subgroups of patients with intermediate or high risk disease that have improved survival outcomes with androgen deprivation therapy, besides patients with localized disease that underwent radiation? Could there be other variables besides PSA and localization of the prostate cancer that should be considered when identifying ADT treatment candidates, or identifying survival trends in these groups? Methods: We are currently analyzing variables present in the National Cancer Database to retrospectively identify predictive factors for overall survival and progression to metastatic castrate resistant prostate cancer in locally advanced prostate cancers treated with ADT. We will evaluate time-to-death from the initiation of ADT and from the diagnosis of metastatic castrate resistant prostate cancer. The following variables in localized, locally advanced, and metastatic prostate cancer will be analyzed with Statistical Analysis Software: age, locally advanced, site-specific metastasis (M1a, M1b, M1c), Gleason score, local treatment (radical prostatectomy or radiation), stage (T, N, and M), prostate lobe (one vs. both; T2a/b vs. T2c), chemotherapy (date, time from M1 stage), comorbidity score, ethnicity, facility type, insurance, and risk groups (low/intermediate/high as per NCCN guidelines).

Sign in / Sign up

Export Citation Format

Share Document